Top entities: ImmunityBio, Rosen Law Firm, Patrick Soon-Shiong.

What category does this event fall under?

Business — classified as securities lawsuit.

What is the sentiment of coverage?

Aggregate sentiment score: -20 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated May 09, 2026. Coverage continues to evolve.

Business securities lawsuit

ImmunityBio Securities Fraud Lawsuit Filed

Q: When did this event occur?

First reported May 01, 2026; last updated May 09, 2026.

Q: What is the market impact?

Direct. The lawsuit against ImmunityBio for alleged securities fraud could lead to a decline in its stock price due to investor concerns and potential financial penalties.

Analysis based on 9 articles · First reported May 01, 2026 · Last updated May 09, 2026

Sentiment

-20

Attention

Articles

Market Impact

Direct

Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard

Market Impact

The lawsuit against ImmunityBio for alleged securities fraud could lead to a decline in its stock price due to investor concerns and potential financial penalties. This event highlights the risks associated with investing in companies where management statements are later found to be misleading.

Biotechnology Legal Services

Event Summary

Rosen Law Firm has filed a securities class action lawsuit against ImmunityBio, a publicly traded company, on behalf of investors who purchased its securities between January 19, 2026, and March 24, 2026. The lawsuit alleges that Patrick Soon-Shiong, a defendant, materially overstated the capabilities of Nogapendekin alfa inbakicept, leading to false and misleading statements about ImmunityBio's business, operations, and prospects. Investors are reminded of the May 26, 2026, lead plaintiff deadline. The firm is encouraging affected investors to join the class action to seek compensation for damages suffered.

Key Actions

100 Rosen Law Firm filed lawsuit ImmunityBio

Entities Involved

stock

ImmunityBio

ImmunityBio is the defendant in a securities class action lawsuit, facing allegations of making false and misleading statements regarding Nogapendekin alfa inbakicept's capabilities, which could negatively impact its stock price and reputation.

Importance 100 Sentiment -50

priv

Rosen Law Firm

Rosen Law Firm initiated and is leading the securities class action lawsuit against ImmunityBio, representing investors who allegedly suffered damages.

Importance 80 Sentiment 20

per

Patrick Soon-Shiong

Patrick Soon-Shiong is a defendant in the lawsuit, accused of materially overstating Nogapendekin alfa inbakicept's capabilities, which could harm his professional reputation.

Importance 70 Sentiment -40

NEWSDESK

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard